Prelude Therapeutics Q2 FY26 net loss narrows to $13.92 million; revenue turns to $5.7 million

Prelude Therapeutics posted Q2 revenue of $5.7 million, swinging from no revenue a year earlier; net loss narrowed to $13.9 million, or $0.14 per share.

R&D expense fell to $16.1 million from $25.8 million, on lower SMARCA2 trial costs after a 2025 pause and a workforce reduction.

Cash, cash equivalents, restricted cash and marketable securities totaled $155.2 million at June 30, with runway expected into Q2 2028.

The company plans to initiate a Phase 1 study of KAT6A degrader PRT13722 in HR+ breast cancer in Q4 2026, pending IND clearance; PRT12396 Phase 1 enrollment continues in PV and MF.